Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NovoCure Ltd (038.BE)

Berlin - Berlin Delayed Price. Currency in EUR
16.34-0.24 (-1.45%)
At close: 09:52PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close16.58
Open16.55
Bid15.95 x 0
Ask16.62 x 0
Day's Range16.23 - 16.56
52 Week Range16.23 - 119.94
Volume33
Avg. Volume1
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 038.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Insider Monkey

      Should You Hold NovoCure Limited (NVCR)?

      ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed the Russell 2000 Index in the second quarter. On an absolute basis, the strategy gained all 11 sectors it invested in during the quarter. IT and industrial […]

    • Business Wire

      Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

      ROOT, Switzerland, September 08, 2023--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis o

    • InvestorPlace

      3 Healthcare Stocks to Sell in September Before They Crash & Burn

      The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price. Healthcare companies can see a massive surge in their share price, following encouraging treatment outcomes, but the reverse is also

    Advertisement
    Advertisement